|
CZ298681B6
(cs)
*
|
1998-06-08 |
2007-12-19 |
F. Hoffmann-La Roche Ag |
Lécivo pro lécení infekcí chronické hepatitis C
|
|
MY164523A
(en)
*
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
|
KR20080021797A
(ko)
|
2000-05-26 |
2008-03-07 |
이데닉스(케이만)리미티드 |
플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
|
|
US7208167B2
(en)
|
2000-08-07 |
2007-04-24 |
Sciclone Pharmaceuticals, Inc. |
Treatment of hepatitis C with thymosin and peptide combination therapy
|
|
IL154299A0
(en)
*
|
2000-08-07 |
2003-09-17 |
Sciclone Pharmaceuticals Inc |
Treatment of hepatitis c with thymosin, interferon and ribavirin
|
|
US7179791B2
(en)
|
2001-01-11 |
2007-02-20 |
Duke University |
Inhibiting GS-FDH to modulate NO bioactivity
|
|
AU2002330154A1
(en)
|
2001-09-28 |
2003-04-07 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
|
KR100480429B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
|
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
|
BR0312271A
(pt)
|
2002-06-28 |
2007-11-06 |
Idenix Cayman Ltd |
compostos, composições e seus usos para o tratamento de infecções por flaviviridae
|
|
PL374781A1
(en)
|
2002-06-28 |
2005-10-31 |
Idenix (Cayman) Limited |
2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
|
NZ537662A
(en)
|
2002-06-28 |
2007-10-26 |
Idenix Cayman Ltd |
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
|
HUE033832T2
(en)
*
|
2002-11-15 |
2018-01-29 |
Idenix Pharmaceuticals Llc |
2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
|
|
RU2005121904A
(ru)
|
2002-12-12 |
2006-01-20 |
Айденикс (Кайман) Лимитед (Ky) |
Способ получения 2`-разветвленных нуклеозидов
|
|
EP1575971A4
(en)
*
|
2002-12-23 |
2008-03-05 |
Idenix Cayman Ltd |
PROCESS FOR THE PREPARATION OF 3-NUCLEOSIDE PRODRUGS
|
|
EP2345657A1
(en)
|
2003-05-30 |
2011-07-20 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
|
EP1912643A2
(en)
*
|
2004-06-23 |
2008-04-23 |
Idenix (Cayman) Limited |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
|
US8886272B2
(en)
|
2004-07-13 |
2014-11-11 |
Dexcom, Inc. |
Analyte sensor
|
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
|
AU2005285045B2
(en)
|
2004-09-14 |
2011-10-13 |
Gilead Sciences, Inc. |
Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
|
WO2006056464A2
(en)
|
2004-11-26 |
2006-06-01 |
Pieris Ag |
Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
|
|
MX2008002015A
(es)
*
|
2005-08-15 |
2008-03-25 |
Hoffmann La Roche |
Polietilenglicol-interferon alfa y ribavirina para el tratamiento del virus de hepatitis b.
|
|
US9201979B2
(en)
*
|
2005-09-14 |
2015-12-01 |
Millennial Media, Inc. |
Syndication of a behavioral profile associated with an availability condition using a monetization platform
|
|
EP1976382B1
(en)
*
|
2005-12-23 |
2013-04-24 |
IDENIX Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
|
JP5711118B2
(ja)
|
2008-06-24 |
2015-04-30 |
テクニッシュ ウニヴェルジテート ミュンヘン |
所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
|
|
PE20110343A1
(es)
*
|
2008-09-17 |
2011-06-25 |
Boehringer Ingelheim Int |
Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina
|
|
KR20110098849A
(ko)
|
2008-12-23 |
2011-09-01 |
파마셋 인코포레이티드 |
뉴클레오시드 유사체
|
|
PT2376088T
(pt)
|
2008-12-23 |
2017-05-02 |
Gilead Pharmasset Llc |
Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
|
|
SG194404A1
(en)
|
2008-12-23 |
2013-11-29 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
|
EP2427213B1
(en)
|
2009-05-08 |
2015-04-01 |
Sciclone Pharmaceuticals, Inc. |
Alpha thymosin peptides as vaccine enhancers
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
JP2013501033A
(ja)
|
2009-08-05 |
2013-01-10 |
ピエリス アーゲー |
リポカリン突然変異タンパク質の制御放出製剤
|
|
EA201200650A1
(ru)
|
2009-10-30 |
2012-12-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
|
|
BR112012013662B1
(pt)
|
2009-12-07 |
2022-08-02 |
Pieris Pharmaceuticals Gmbh |
Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
|
|
PT2609923T
(pt)
|
2010-03-31 |
2017-08-30 |
Gilead Pharmasset Llc |
Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
|
|
RU2569745C2
(ru)
|
2010-06-08 |
2015-11-27 |
Пиерис АГ |
Мутеины липокалина слезы, связывающие альфа il-4 r
|
|
NZ606584A
(en)
|
2010-08-16 |
2014-10-31 |
Pieris Ag |
Binding proteins for hepcidin
|
|
US9260492B2
(en)
|
2010-11-15 |
2016-02-16 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
|
|
AU2011336632B2
(en)
|
2010-11-30 |
2015-09-03 |
Gilead Pharmasset Llc |
Compounds
|
|
EP2646552B1
(en)
|
2010-12-02 |
2017-07-05 |
Pieris Pharmaceuticals GmbH |
Muteins of human lipocalin 2 with affinity for ctla-4
|
|
PL2709613T5
(pl)
|
2011-09-16 |
2020-12-14 |
Gilead Pharmasset Llc |
Metody leczenia hcv
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
ES2710384T3
(es)
|
2011-12-13 |
2019-04-24 |
Pieris Pharmaceuticals Gmbh |
Procedimientos para la prevención o el tratamiento de determinados trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores
|
|
WO2013174783A1
(en)
|
2012-05-23 |
2013-11-28 |
Pieris Ag |
Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
|
|
US20140039923A1
(en)
*
|
2012-08-03 |
2014-02-06 |
AxelaCare Health Solutions, Inc. |
Computer program, method, and system for receiving and managing patient data gathered during patient treatments
|
|
WO2014076321A1
(en)
|
2012-11-19 |
2014-05-22 |
Pieris Ag |
Novel specific-binding polypeptides and uses thereof
|
|
PT2950786T
(pt)
|
2013-01-31 |
2020-03-03 |
Gilead Pharmasset Llc |
Formulação de combinação de dois compostos antivirais
|
|
HK1213194A1
(zh)
|
2013-03-14 |
2016-06-30 |
Daiichi Sankyo Co., Ltd. |
用於新型的结合蛋白质pcsk9
|
|
EA201690473A1
(ru)
|
2013-08-27 |
2017-03-31 |
ГАЙЛИД ФАРМАССЕТ ЭлЭлСи |
Комбинированный состав двух противовирусных соединений
|
|
EP3094650A2
(en)
|
2014-01-13 |
2016-11-23 |
Pieris Pharmaceuticals GmbH |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
SG11201609274SA
(en)
|
2014-05-22 |
2016-12-29 |
Pieris Pharmaceuticals Gmbh |
Novel specific-binding polypeptides and uses thereof
|
|
JP6839087B2
(ja)
|
2015-01-28 |
2021-03-03 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
血管新生に特異的な新規のタンパク質
|
|
TN2017000348A1
(en)
|
2015-02-18 |
2019-01-16 |
Sanofi Sa |
Novel proteins specific for pyoverdine and pyochelin
|
|
KR20170138574A
(ko)
|
2015-05-04 |
2017-12-15 |
피어이스 파마슈티컬즈 게엠베하 |
항암 융합 폴리펩타이드
|
|
KR102734408B1
(ko)
|
2015-05-04 |
2024-11-27 |
피어이스 파마슈티컬즈 게엠베하 |
Cd137에 특이적인 신규한 단백질
|
|
AU2016262838B2
(en)
|
2015-05-18 |
2020-10-08 |
Pieris Pharmaceuticals Gmbh |
Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
|
|
MX390894B
(es)
|
2015-05-18 |
2025-03-21 |
Pieris Pharmaceuticals Gmbh |
Polipéptido de fusión anti-cáncer.
|
|
EP3115371A1
(en)
|
2015-07-07 |
2017-01-11 |
Sanofi |
Fusion molecules
|
|
KR20180029238A
(ko)
|
2015-07-15 |
2018-03-20 |
피어이스 파마슈티컬즈 게엠베하 |
Lag-3에 특이적인 신규 단백질
|
|
CN108699162A
(zh)
|
2015-11-30 |
2018-10-23 |
皮里斯澳大利亚有限公司 |
新型抗血管生成融合多肽
|
|
TW201725212A
(zh)
|
2015-12-10 |
2017-07-16 |
第一三共股份有限公司 |
特異性於降鈣素基因相關胜肽的新穎蛋白
|
|
WO2018087108A1
(en)
|
2016-11-09 |
2018-05-17 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for cd137
|
|
WO2018134274A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for lag-3
|
|
CA3100119A1
(en)
|
2018-07-31 |
2020-02-06 |
Pieris Pharmaceuticals Gmbh |
Fusion protein specific for cd137 and pd-l1
|
|
MX2021010039A
(es)
|
2019-02-26 |
2021-09-21 |
Pieris Pharmaceuticals Gmbh |
Novedosas proteinas de fusion especificas para cd137 y gpc3.
|
|
AU2021285201A1
(en)
|
2020-06-05 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Multimeric immunomodulator targeting 4-1BB
|
|
EP4320141A1
(en)
|
2021-04-08 |
2024-02-14 |
Pieris Pharmaceuticals GmbH |
Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
|
|
WO2022243341A1
(en)
|
2021-05-18 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for ox40
|
|
KR20250071257A
(ko)
|
2022-09-21 |
2025-05-21 |
씨젠 인크. |
Cd137 및 cd228에 특이적인 신규한 융합 단백질
|
|
WO2025175123A1
(en)
|
2024-02-16 |
2025-08-21 |
Seagen Inc. |
Methods of treating cancer using fusion proteins specific for cd137 and cd228
|